Search Result

Results for "

Anti-drug resistance

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Bacterial (3) Cytochrome P450 (2) Fungal (2) HIV (1) Isotope-Labeled Compounds (1) Reference Standards (1) Reverse Transcriptase (1) SARS-CoV (1) Virus Protease (1)
By Research Areas:	Infection (7)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Drug Intermediate Drug Isomer Drug Derivative Drug Metabolite Antibody-Drug Conjugates (ADCs) Peptide-Drug Conjugates (PDCs) Radionuclide-Drug Conjugates (RDCs) Drug-Linker Conjugates for ADC BCRP ADC Linker P-glycoprotein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157403

Jun12682	Virus Protease SARS-CoV	Infection
Jun12682 is an orally active SARS-CoV-2 papain-like protease (PL ^pro) inhibitor, with a K_i value of 37.7 nM and an EC₅₀ value of 1.1 μM in the FlipGFP PL ^pro assay. Jun12682 has efficacy in hindering PL ^pro both deubiquitination and deISGylation, with K_i values of 63.5 and 38.5 nM, respectively. Jun12682 exhibits resistance in multiple PL ^pro mutant strains, and its enzymatic activity is comparable to that of the wild-type. Jun12682 can be used for the study of the SARS-CoV-2 .

HY-B1329

Apramycin sulfate 3 Publications Verification Nebramycin II sulfate	Bacterial Antibiotic	Infection
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .

HY-174353S

CYP51-IN-23-d3	Isotope-Labeled Compounds Cytochrome P450 Fungal	Infection
CYP51-IN-23-d₃ is a potent and broad-spectrum CYP51 inhibitor with a MIC₈₀ of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d₃ can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d₃ exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d₃ can be used for the study of invasive fungal infections (IFIs) .

HY-174353

CYP51-IN-22	Cytochrome P450 Fungal	Infection
CYP51-IN-22, the non-deuterated analog of CYP51-IN-23-d₃ (HY-174353S), is a potent and broad-spectrum CYP51 inhibitor.CYP51-IN-22 inhibits Aspergillus fumigatum with a MIC₈₀ of 1 μg/mL. CYP51-IN-22 can prevent fungal phase transformation and biofilm formation. CYP51-IN-22 exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-22 can be used for the study of invasive fungal infections (IFIs) .

HY-17558

Apramycin Nebramycin II	Bacterial Antibiotic	Infection
Apramycin (Nebramycin II) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

HY-175351

HIV-1-IN-83	HIV Reverse Transcriptase	Infection
HIV-1-IN-83 (Compound 18E) is a HIV-1 non-nucleoside reverse transcriptase inhibitor with an IC₅₀ of 0.45 μM for wild-type HIV-1 non-nucleoside reverse transcriptase. HIV-1-IN-83 has potent antiviral activity against both HIV-1 wild-type and mutant strains and improves antidrug resistance for Y188L and RES056 mutant strains. HIV-1-IN-83 has no significant toxicity up to 11.088 μM .

HY-B1329R

Apramycin sulfate (Standard) Nebramycin II sulfate (Standard)	Reference Standards Bacterial Antibiotic	Infection
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

Cat. No.	Product Name

HY-L169

Anti-Drug-Resistant Compound Library	521 compounds
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important. MCE designs a unique collection of 521 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

Anti-Drug-Resistant Compound Library

521 compounds

Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.

MCE designs a unique collection of 521 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-B1329

Apramycin sulfate 3 Publications Verification Nebramycin II sulfate	Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Animal Husbandry Antibacterial Disease Research Disease Research Fields Other Antibiotics Cancer	Bacterial Antibiotic
Apramycin (EBL 1003) sulfate is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin sulfate is a potential anti-drug-resistance antibiotic .

HY-B1329R

Apramycin sulfate (Standard) Nebramycin II sulfate (Standard)	Structural Classification Microorganisms Antibiotics Source classification Animal Husbandry Antibacterial Disease Research Other Antibiotics	Reference Standards Bacterial Antibiotic
Apramycin (sulfate) (Standard) is the analytical standard of Apramycin (sulfate). This product is intended for research and analytical applications. Apramycin (EBL 1003) is an orally active, acidic pH tolerant and aminoglycoside-modifying-enzymes-tolerant aminoglycoside antibiotic which inhibits protein biosynthesis by targeting the bacterial ribosome. Apramycin is a potential anti-drug-resistance antibiotic .

Cat. No.	Product Name	Chemical Structure

HY-174353S

CYP51-IN-23-d3
CYP51-IN-23-d₃ is a potent and broad-spectrum CYP51 inhibitor with a MIC₈₀ of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d₃ can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d₃ exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d₃ can be used for the study of invasive fungal infections (IFIs) .

CYP51-IN-23-d3

CYP51-IN-23-d₃ is a potent and broad-spectrum CYP51 inhibitor with a MIC₈₀ of 1 μg/mL against Aspergillus fumigatum. CYP51-IN-23-d₃ can prevent fungal phase transformation and biofilm formation. CYP51-IN-23-d₃ exhibits anti-drug resistance activity and fungal activity, and shows excellent safety for cells and significant pharmacological activity in mice. CYP51-IN-23-d₃ can be used for the study of invasive fungal infections (IFIs) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks